X4 Pharmaceuticals, Inc. (XFOR)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 1.8M | 2.6M | 2.7M | 8.8M |
| Gross Profit | 1.4M | 2.2M | 2.1M | 7.2M |
| Operating Income | (27.5M) | (23.7M) | (20.3M) | (16.4M) |
| Net Income | (29.8M) | (23.9M) | (20.2M) | (16.2M) |
| Diluted EPS | $-0.69 | N/A | $-0.16 | $-0.13 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.6M | 35.1M |
| Gross Profit | 0.00 | 0.00 | 1.8M | 29.4M |
| Operating Income | (88.1M) | (107.5M) | (141.4M) | (86.9M) |
| Net Income | (93.9M) | (101.2M) | (37.5M) | (79.2M) |
| Diluted EPS | $-45.60 | $-17.07 | $-5.70 | $-1.87 |